Stock listing
Stockholm:SPRINT Sprint Bioscience AB Aktie
Home listing (Stockholm) of Sprint Bioscience AB
Follow Sprint Bioscience AB into a list and get an email when it puts out news.
Share price · OMXSTO:SPRINT
3.68 SEK -0.24 (-6.1%)
Close on Nov 20, 2026
- Day range
- 3.57 – 3.95 SEKNov 20, 2026
- Volume
- 195,798 sharesNov 20, 2026
- Market cap
- 388.3M SEKAt the close on Nov 20, 2026 · price × 105.5M shares outstanding
- 52-week range
- 0.578 – 4.59 SEKLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- 1.01M SEKMedian day 242,497 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Stockholm:SPRINT · Home | 3.68 SEK | -0.24 (-6.1%) | 195,798 | 3.95 | 3.95 | 3.57 | 3.92 | Close on Nov 20, 2026 |
| Munich:5JA1 | €0.351 EUR | 0.000 (0.0%) | — | €0.351 | €0.351 | €0.351 | €0.351 | Close on Nov 20, 2026 |
| Frankfurt:5JA1 | €0.307 EUR | -0.024 (-7.3%) | — | €0.319 | €0.319 | €0.307 | €0.331 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OMXSTO:SPRINT · SEK, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| 3.68 | -0.24 | -6.1% | 3.95 | 3.95 | 3.57 | 195,798 | |
| 3.92 | -0.03 | -0.8% | 3.94 | 3.94 | 3.83 | 112,754 | |
| 3.95 | -0.04 | -1.0% | 3.93 | 3.99 | 3.83 | 243,484 | |
| 3.99 | +0.12 | +3.1% | 3.79 | 4.00 | 3.78 | 415,201 | |
| 3.87 | +0.09 | +2.4% | 3.84 | 3.95 | 3.75 | 566,278 | |
| 3.78 | -0.25 | -6.2% | 4.03 | 4.09 | 3.73 | 491,273 | |
| 4.03 | +0.03 | +0.8% | 3.83 | 4.10 | 3.72 | 654,434 | |
| 4.00 | +0.35 | +9.6% | 3.64 | 4.00 | 3.55 | 470,334 | |
| 3.65 | +0.16 | +4.6% | 3.43 | 3.69 | 3.39 | 347,906 | |
| 3.49 | +0.06 | +1.7% | 3.41 | 3.52 | 3.40 | 106,291 | |
| 3.43 | +0.07 | +2.1% | 3.38 | 3.58 | 3.32 | 330,296 | |
| 3.36 | -0.24 | -6.7% | 3.58 | 3.63 | 3.36 | 379,140 | |
| 3.60 | +0.10 | +2.9% | 3.63 | 3.63 | 3.51 | 16,849 | |
| 3.50 | +0.06 | +1.7% | 3.41 | 3.70 | 3.41 | 290,890 | |
| 3.44 | +0.03 | +0.9% | 3.42 | 3.51 | 3.41 | 85,768 | |
| 3.41 | -0.04 | -1.2% | 3.45 | 3.45 | 3.33 | 102,608 | |
| 3.45 | +0.11 | +3.3% | 3.28 | 3.46 | 3.28 | 227,690 | |
| 3.34 | -0.01 | -0.3% | 3.35 | 3.39 | 3.25 | 49,508 | |
| 3.35 | -0.25 | -6.9% | 3.57 | 3.57 | 3.25 | 445,818 | |
| 3.60 | +0.14 | +4.0% | 3.52 | 3.63 | 3.50 | 61,451 | |
| 3.46 | -0.08 | -2.3% | 3.47 | 3.62 | 3.46 | 41,370 | |
| 3.54 | -0.01 | -0.3% | 3.52 | 3.62 | 3.43 | 303,932 | |
| 3.55 | -0.06 | -1.7% | 3.53 | 3.73 | 3.53 | 119,371 | |
| 3.61 | -0.22 | -5.7% | 3.75 | 3.76 | 3.52 | 228,072 | |
| 3.83 | +0.01 | +0.3% | 3.82 | 3.88 | 3.71 | 57,904 | |
| 3.82 | +0.07 | +1.9% | 3.72 | 3.88 | 3.67 | 341,205 | |
| 3.75 | +0.10 | +2.7% | 3.63 | 3.80 | 3.62 | 223,947 | |
| 3.65 | +0.01 | +0.3% | 3.59 | 3.72 | 3.56 | 392,328 | |
| 3.64 | +0.15 | +4.3% | 3.48 | 3.66 | 3.35 | 429,220 | |
| 3.49 | +0.03 | +0.9% | 3.46 | 3.62 | 3.37 | 188,324 | |
| 3.46 | -0.12 | -3.4% | 3.57 | 3.67 | 3.46 | 123,177 | |
| 3.58 | +0.05 | +1.4% | 3.56 | 3.65 | 3.40 | 207,045 | |
| 3.53 | -0.04 | -1.1% | 3.46 | 3.57 | 3.40 | 163,366 | |
| 3.57 | +0.17 | +5.0% | 3.41 | 3.57 | 3.40 | 577,486 | |
| 3.40 | +0.10 | +3.0% | 3.32 | 3.45 | 3.25 | 447,904 | |
| 3.30 | +0.18 | +5.8% | 3.09 | 3.33 | 3.09 | 574,593 | |
| 3.12 | +0.07 | +2.3% | 3.00 | 3.20 | 2.96 | 141,219 | |
| 3.05 | +0.27 | +9.7% | 2.80 | 3.17 | 2.79 | 241,509 | |
| 2.78 | +0.01 | +0.4% | 2.71 | 2.79 | 2.65 | 82,859 | |
| 2.77 | -0.08 | -2.8% | 2.80 | 2.86 | 2.55 | 115,101 | |
| 2.85 | -0.01 | -0.3% | 2.86 | 2.86 | 2.76 | 89,436 | |
| 2.86 | -0.09 | -3.1% | 2.95 | 2.98 | 2.81 | 90,099 | |
| 2.95 | 0.00 | 0.0% | 2.95 | 2.96 | 2.79 | 302,696 | |
| 2.95 | +0.05 | +1.7% | 2.84 | 2.96 | 2.75 | 363,948 | |
| 2.90 | +0.12 | +4.3% | 2.80 | 2.95 | 2.72 | 372,499 | |
| 2.78 | +0.04 | +1.5% | 2.74 | 2.82 | 2.71 | 83,496 | |
| 2.74 | 0.00 | 0.0% | 2.69 | 2.84 | 2.64 | 153,490 | |
| 2.74 | 0.00 | 0.0% | 2.72 | 2.74 | 2.55 | 1,252,178 | |
| 2.74 | -0.14 | -4.9% | 2.91 | 3.00 | 2.68 | 799,244 | |
| 2.88 | -0.31 | -9.7% | 3.13 | 3.14 | 2.84 | 891,948 | |
| 3.19 | -0.05 | -1.5% | 3.20 | 3.20 | 3.13 | 55,563 | |
| 3.24 | -0.01 | -0.3% | 3.26 | 3.27 | 3.13 | 127,187 | |
| 3.25 | -0.04 | -1.2% | 3.25 | 3.26 | 3.13 | 173,438 | |
| 3.29 | +0.01 | +0.3% | 3.22 | 3.35 | 3.22 | 110,005 | |
| 3.28 | -0.02 | -0.6% | 3.30 | 3.38 | 3.19 | 312,923 | |
| 3.30 | +0.10 | +3.1% | 3.12 | 3.30 | 3.10 | 268,442 | |
| 3.20 | +0.02 | +0.6% | 3.12 | 3.28 | 3.10 | 178,120 | |
| 3.18 | -0.11 | -3.3% | 3.22 | 3.28 | 3.08 | 343,872 | |
| 3.29 | +0.08 | +2.5% | 3.16 | 3.33 | 3.10 | 365,085 | |
| 3.21 | +0.06 | +1.9% | 3.00 | 3.23 | 2.98 | 313,756 | |
| 3.15 | 0.00 | 0.0% | 3.16 | 3.17 | 3.00 | 113,979 | |
| 3.15 | -0.02 | -0.6% | 3.17 | 3.21 | 3.00 | 375,413 | |
| 3.17 | +0.16 | +5.3% | 3.08 | 3.18 | 2.98 | 344,519 | |
| 3.01 | -0.28 | -8.5% | 3.26 | 3.36 | 2.77 | 1,367,233 |
Splits
3 splits since 2021 · OMXSTO:SPRINT · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 60-for-59 | Split | |
| 47-for-40 | Split | |
| 21-for-20 | Split |
- Ticker
- Stockholm:SPRINT
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Stockholm
- Currency
- SEK
What changed lately
Latest news release · Nov 9, 2026
Nomination Committee Appointed for the 2027 Annual General Meeting of Sprint Bioscience
Latest news
Nomination Committee Appointed for the 2027 Annual General Meeting of Sprint Bioscience
Nov 9, 2026
Closed 4.03 (+0.8%) on Nov 11, 2026
Sprint Bioscience announces agreement with Lilly TuneLab to accelerate drug development
Jul 23, 2026
Closed 3.75 (+4.7%) on Jul 23, 2026
Sprint Bioscience (publ) announces that Aktiespararna initiates commissioned research coverage of the company
Jun 4, 2026
Closed 3.31 (-5.4%) on Jun 4, 2026
Sprint Bioscience completes strategic STK25 evaluation; continued focus on the primary indication
Apr 16, 2026
Closed 3.29 (-15.0%) on Apr 16, 2026
Sprint Bioscience appoints Jenni Björnulfson as CFO
Apr 1, 2026
Closed 2.60 (+9.2%) on Apr 1, 2026
Sprint Bioscience sells the TREX1 program to Gilead
Nov 24, 2025
Closed 1.44 (+116.2%) on Nov 24, 2025
Sprint Bioscience AB on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 6 in the last 12 months · 6 in all · newest Nov 9, 2026 · oldest 2025
- Decks
- 1 deck · latest Apr 24, 2025
Where Sprint Bioscience AB is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Stockholm:SPRINT · Home listing · This page | Stockholm | Sweden | SEK |
| gettex:5JA1 | gettex | Germany | EUR |
| LS Exchange:A14NY2 | LS Exchange | Germany | EUR |
| Lang & Schwarz:A14NY2 | Lang & Schwarz | Germany | EUR |
| Munich:5JA1 | Munich | Germany | EUR |
| Frankfurt:5JA1 | Frankfurt | Germany | EUR |
| Stuttgart:5JA1 | Stuttgart | Germany | EUR |
Valuation
EV/sales 2.1× against a median of 33.8×: 2nd lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- 295.0M SEK
- P/E
- 5.1×
- EV/sales
- 2.1×
- EV/EBITDA
- 3.7×
- Price/book
- 4.3×
- Gross margin
- 78.0%
- Operating margin
- 56.2%
- Net margin
- 54.4%
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Sprint Bioscience AB · OMXSTO:SPRINT | US$37.98M | US$28.86M | 5.1× | 2.1× | 3.7× | 4.3× | 54.4% | 0.0× | n/a |
| Herantis Pharma PLC · OMXHEX:HRTIS | US$38.69M | US$38.62M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Harvard Apparatus Regenerative Technology Inc · OTC:HRGN | US$38.54M | US$36.69M | n/a | 36.5× | n/a | 73.8× | −642.0% | 0.0× | 0.09 |
| Quratis Inc. · KRX:348080 | US$38.36M | US$29.47M | n/a | 36.2× | n/a | 1.1× | n/a | 0.0× | n/a |
| OSE Immunotherapeutics SA · EURONEXT:OSE | US$38.31M | US$52.28M | n/a | 18.2× | n/a | 1.3× | n/a | 1.3× | n/a |
| KoBioLabs, Inc. · KRX:348150 | US$38.23M | US$6.96M | n/a | 0.1× | n/a | 1.8× | −6.4% | 0.2× | n/a |
| Theralase Technologies Inc. · TSXV:TLT | US$37.89M | US$34.22M | n/a | 61.1× | n/a | 7.9× | −472.5% | 0.0× | 0.75 |
| Connect Biopharma Holdings Limited · NASDAQ:CNTB | US$37.15M | US$18.16M | n/a | 4.9× | n/a | 3.1× | n/a | 0.0× | 0.93 |
| Coiled Therapeutics PLC · LSE:COIL | US$37.13M | US$30.46M | n/a | n/a | n/a | 0.6× | n/a | 0.0× | n/a |
| TaiRx, Inc. · TPEX:6580 | US$37.08M | US$28.62M | n/a | 33.8× | n/a | 3.3× | −793.3% | 0.0× | n/a |
| Pliant Therapeutics, Inc. · NASDAQ:PLRX | US$36.89M | −US$104.2M | n/a | n/a | n/a | 0.3× | n/a | 0.0× | 1.06 |
| Median of the others | US$38.06M | US$29.97M | 33.8× | 1.8× | −557.3% | 0.0× | 0.84 |
Forecasts
Analysts' consensus from EODHD, read Nov 16, 2026. Not 6ix's view and not investment advice.
- Price target
- 5.10 SEK · Analysts' mean
- EPS, year to Dec 2026
- 0.30 · 1 analyst
- Revenue, year to Dec 2026
- 86.8M · 1 analyst
Team and board
| Officer | Role |
|---|---|
| Johan Emilsson | CEO |
| Jenni Björnulfson | CFO |
| Lionel Trésaugues | Director of Structure-Based Drug Design |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q1 2026 | May 25, 2026 · Before open | +8.3% |
| Q4 2025 | Feb 11, 2026 · Before open | −9.1% |
| Q3 2025 | Nov 25, 2025 · Before open | +4.2% |
| Q2 2025 | Aug 27, 2025 · Before open | −4.4% |
| Q1 2025 | May 27, 2025 · Before open | 0.0% |
| Q4 2024 | Feb 12, 2025 · Before open | +6.2% |
| Q3 2024 | Oct 30, 2024 · Before open | −17.4% |
| Q2 2024 | Aug 28, 2024 · Before open | −3.9% |
| Q1 2024 | May 8, 2024 · Before open | +0.3% |
| Q4 2023 | Feb 14, 2024 · Before open | +4.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q3 2023 | Oct 25, 2023 · Before open | +9.2% |
| Q2 2023 | Aug 24, 2023 · Before open | +5.9% |
| Q1 2023 | May 10, 2023 · Before open | +0.9% |
| Q4 2022 | Feb 15, 2023 · Before open | −0.7% |
| Q3 2022 | Oct 26, 2022 · After close | |
| Q2 2022 | Aug 24, 2022 · After close | +3.6% |
| Q1 2022 | May 11, 2022 · After close | +1.7% |
| Q4 2021 | Feb 16, 2022 · Before open | −1.8% |
| Q3 2021 | Oct 27, 2021 · Before open | −1.7% |
| Quarter to Jun 30, 2021 | Aug 13, 2021 · Before open | −1.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Fact Sheet (April 2025) | Fact sheet | 7 slides | Apr 24, 2025 |
Financials
Annual, in SEK
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 167.2M | 65.6M | 50.5M | 83.0K | 35.1M | 16.9M | 33.5M | 17.9M | 24.0M | 35.0M |
| Cost of revenue | 69.8M | 28.3M | 8.70M | 61.0M | 10.4M | 10.5M | 8.17M | 745.0K | 2.99M | 418.5K |
| Gross profit | 97.3M | 37.3M | 41.8M | -60.9M | 24.7M | 6.43M | 25.4M | 17.2M | 21.0M | 34.6M |
| Research and development | 2.88M | |||||||||
| Selling, general and administrative | 34.1M | 33.6M | 26.4M | 31.4M | 22.2M | 21.1M | 18.3M | 17.2M | 13.2M | 11.1M |
| Operating income | 97.3M | -19.7M | -845.0K | -60.9M | -25.5M | -37.7M | -20.4M | -22.1M | -10.7M | 4.57M |
| Depreciation and amortization | 1.07M | 958.0K | 447.0K | 618.0K | 590.0K | 697.0K | 731.0K | 704.0K | 564.0K | 451.2K |
| EBITDA | 98.4M | -18.7M | -398.0K | -60.3M | -24.9M | -37.0M | -19.7M | -21.4M | -10.1M | 5.02M |
| Interest expense | 6.21M | 40.0K | 387.0K | 42.0K | 269.0K | 3.44M | 1.21M | 137.0K | 42.0K | 84.7K |
| Income before tax | 91.7M | -18.3M | -438.0K | -60.2M | -25.1M | -42.8M | -21.5M | -22.2M | -10.7M | 4.54M |
| Income tax | 279.1K | 741.0K | 269.0K | 3.44M | 1.21M | 7.00K | -292.0K | 221.7K | ||
| Net income | 91.7M | -18.3M | -438.0K | -60.2M | -25.4M | -46.2M | -22.7M | -22.2M | -10.7M | 4.54M |
| Earnings per share, basic | 0.99 | -0.26 | -0.01 | -1.43 | -0.73 | -2.23 | -1.51 | -1.88 | -1.09 | 0.50 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 126.7M | 25.1M | 49.9M | 29.5M | 70.6M | 27.1M | 8.38M | 14.7M | 1.48M | 23.6M |
| Receivables | 6.17M | 12.2M | 7.94M | 3.38M | 2.99M | 2.79M | 5.28M | 219.0K | 2.69M | 1.87M |
| Inventory | -7.14M | -1.00K | 1 | 1.91M | 1 | -219.0K | -692.0K | -2.67M | ||
| Current assets | 132.9M | 37.2M | 57.9M | 34.9M | 75.9M | 32.3M | 17.4M | 18.3M | 4.88M | 26.9M |
| Property, plant and equipment | 3.74M | 4.72M | 4.38M | 2.37M | 2.99M | 872.0K | 1.57M | 2.21M | 1.51M | 1.87M |
| Total assets | 136.7M | 42.1M | 62.4M | 37.4M | 79.1M | 33.4M | 19.2M | 59.3M | 35.5M | 49.5M |
| Accounts payable | 4.40M | 5.44M | 5.71M | 3.73M | 2.92M | 3.40M | 2.59M | 4.71M | 3.39M | 3.62M |
| Current liabilities | 17.5M | 32.8M | 34.6M | 9.23M | 8.68M | 24.3M | 8.23M | 22.0M | 7.40M | 21.0M |
| Long-term debt | 0 | 0 | ||||||||
| Total debt | 10.0M | 12.0M | 769.2K | |||||||
| Total liabilities | 17.5M | 32.8M | 34.6M | 9.23M | 8.68M | 24.3M | 8.23M | 22.0M | 7.40M | 21.0M |
| Shareholders' equity | 119.2M | 9.27M | 27.8M | 28.2M | 70.5M | 9.14M | 11.0M | 37.2M | 28.1M | 28.5M |
| Shares outstanding | 92.6M | 69.8M | 69.8M | 42.1M | 34.7M | 20.7M | 15.0M | 11.8M | 9.81M | 9.12M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 83.5M | -23.4M | 22.9M | -59.1M | -40.1M | -32.2M | -28.0M | -19.1M | -23.1M | 7.93M |
| Capital spending | -94.0K | -1.30M | -2.45M | -2.00K | -2.71M | -2.71M | -93.0K | -11.1M | -8.56M | -9.91M |
| Free cash flow | 83.4M | -24.7M | 20.4M | -59.1M | -42.8M | -32.2M | -28.1M | -30.2M | -31.6M | -1.97M |
| Cash from investing | -54.0K | -1.30M | -2.45M | 0 | -2.71M | -2.71M | -389.0K | -11.1M | -8.56M | -9.91M |
| Cash from financing | 18.2M | -225.0K | 24.0K | 17.9M | 86.4M | 50.9M | 22.1M | 43.4M | 9.49M | 17.8M |
| Share buybacks | 18.2M | -225.0K | 24.0K | 17.9M | 88.8M | 48.9M | 36.2M | 37.9M | 10.3M | 18.6M |
| Change in cash | 101.6M | -24.9M | 20.4M | -41.2M | 43.6M | 18.7M | -6.31M | 13.2M | -22.1M | 16.0M |
Cap table
Built by 6ix from Sprint Bioscience AB’s releases
- Common shares
- 105,515,538
- Fully diluted
- 105,515,538
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 105,515,538 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 105,515,538 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Jenni Björnulfson | CFO · Since at least Apr 1, 2026 |
| Johan Emilsson | CEO · Since at least Jul 23, 2026 |
Log in to ask 6ix AI your own questions about Sprint Bioscience AB.